Genelux (United States)

Genelux (United States)

Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Genelux (United States), United States, covering academic research published from 2003 to 2023. Read More.


Open Access Percentage

68%


Total
Publications

145


Total Open
Publications

99


Total
Citations

5K


Open Access
Percentage

68%


Total
Publications

145


Total Open
Publications

99


Total
Citations

5K

Wikipedia

Website

download

Breakdown

14% 46% 8% 32%

Publisher Open

14%

Both

46%

Other Platform Open

8%

Closed

32%

Percentage of Open Access over time

200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0246810121416182022Total Publications
200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

62%OA Journal

OA Journal 62%

54

Hybrid 13%

11

No Guarantees 25%

22

Other Platform Open

Domain 94%

73

Institution 58%

45

Public 14%

11

Other Internet 5%

4

Preprint 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
73
University of Würzburg
Institution
35
doaj.org OAI-PMH Repository
Institution
23
Figshare
Public
11
Europe PMC
Domain
4
DOI
Other Internet
4
Unknown Repository
Other Internet
2
University of Milano-Bicocca
Institution
1
University of Milan
Institution
1
University of Genoa
Institution
1
1 / 2

Data updated 12 August 2026

Share

Share

Share